Supplementary protection
LT - Kristalinė (R)-2-[[[3-metil-4-(2,2,2-trifluoretoksi)-2-piridinil]metil]sulfinil]-1H-benzimidazolo forma
EN - CRYSTALLINE FORM OF (R)-2-[[[3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL]METHYL]SULFINYL]-1H-BENZIMIDAZOLE
SPC
| (11) |
Number of the document |
C 1129088 |
| (68) |
Number of the document |
1129088
|
| (21) |
Application number for Supplementary Protection Certificate |
PA 2014 014 |
| (22) |
Date of filing the application |
2014-03-13 |
| (41) |
Date of publication of the application |
2014-04-25 |
|
Date of publication of SPC |
2014-10-27 |
| (24) |
Date of coming into effect of SPC |
2020-06-16 |
Applicant
| (71) |
Takeda Pharmaceutical Company Limited,
1-1, Doshomachi 4-chome, Chuo-ku, Osaka,
JP
|
Grantee
| (73) |
Takeda Pharmaceutical Company Limited,
1-1, Doshomachi 4-chome, Chuo-ku, Osaka,
JP
|
Attorney or representative
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
Number and date of the first national authorization to place the medicinal or plant protection product on the market
| (92) |
LT/1/13/3415/001 - LT/1/13/3415/004, 2013 10 31 LT/1/13/3416/001 - LT/1/13/3416/004, 2013-10-31
|
Calculated date of expiry of the SPC
| (94) |
2025-06-16 |
Name of the product protected by the basic patent
| (95) |
Dexlansoprazolum |
Last renewal fee
|
Payment date |
Validity (years) |
Amount |
|
2024-05-21 |
|
347.00
EUR
|
